Ticker

No recent analyst price targets found for MNOV.

Latest News for MNOV

MediciNova to Participate at the 38th Annual ROTH Conference

LA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer will participate at the 38th Annual ROTH Conference. The conference is…

GlobeNewsWire • Mar 16, 2026
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of the end of January 2026, 12 sites in the US are activated and 100 patients have been enrolled in the SEANOBI study (Scalable Expanded Access with Analysis of Neurofilament…

GlobeNewsWire • Jan 29, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for MNOV.

No House trades found for MNOV.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top